Xiaogang Shu

1.3k total citations
23 papers, 840 citations indexed

About

Xiaogang Shu is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Xiaogang Shu has authored 23 papers receiving a total of 840 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Molecular Biology and 8 papers in Cancer Research. Recurrent topics in Xiaogang Shu's work include Cancer Cells and Metastasis (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Genetic factors in colorectal cancer (4 papers). Xiaogang Shu is often cited by papers focused on Cancer Cells and Metastasis (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Genetic factors in colorectal cancer (4 papers). Xiaogang Shu collaborates with scholars based in China. Xiaogang Shu's co-authors include Zili Zhou, Shengbo Han, Jinhuang Chen, Wenzheng Yuan, Zhengyi Liu, Yan Shu, Qiang Tang, Ning Zhao, Bin Chen and Jintong Ji and has published in prestigious journals such as Gastroenterology, PLoS ONE and British Journal of Cancer.

In The Last Decade

Xiaogang Shu

23 papers receiving 835 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaogang Shu China 14 422 246 226 161 112 23 840
Maoming Xiong China 16 331 0.8× 246 1.0× 213 0.9× 157 1.0× 89 0.8× 47 874
Shuangfeng Chen China 15 308 0.7× 175 0.7× 156 0.7× 110 0.7× 59 0.5× 56 833
Ibrahim Y. Hachim United Arab Emirates 16 367 0.9× 262 1.1× 119 0.5× 133 0.8× 67 0.6× 56 815
Fangxu Tang China 10 317 0.8× 191 0.8× 266 1.2× 103 0.6× 77 0.7× 18 753
Minghua Ge China 15 270 0.6× 186 0.8× 112 0.5× 54 0.3× 46 0.4× 51 734
Liyun Cao United States 14 350 0.8× 279 1.1× 133 0.6× 49 0.3× 68 0.6× 25 945
Yao Xie China 13 308 0.7× 276 1.1× 124 0.5× 58 0.4× 43 0.4× 43 822
Jiaqi Zhu United States 19 365 0.9× 70 0.3× 163 0.7× 136 0.8× 74 0.7× 51 1000
Zhilei Lv China 13 303 0.7× 300 1.2× 157 0.7× 78 0.5× 28 0.3× 25 935
Lijuan Fang China 12 320 0.8× 149 0.6× 122 0.5× 40 0.2× 34 0.3× 42 645

Countries citing papers authored by Xiaogang Shu

Since Specialization
Citations

This map shows the geographic impact of Xiaogang Shu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaogang Shu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaogang Shu more than expected).

Fields of papers citing papers by Xiaogang Shu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaogang Shu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaogang Shu. The network helps show where Xiaogang Shu may publish in the future.

Co-authorship network of co-authors of Xiaogang Shu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaogang Shu. A scholar is included among the top collaborators of Xiaogang Shu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaogang Shu. Xiaogang Shu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Xianguo, Ke An, Zhenzhen Wang, et al.. (2023). Temsirolimus is a promising immunomodulatory agent for enhanced transplantation outcomes. Transplant Immunology. 81. 101952–101952. 1 indexed citations
2.
Zhou, Zili, Ning Zhao, Haijun Bao, et al.. (2022). Increasing rate of hospitalization for severe peptic ulcer in digestive disease emergencies after the pandemic. Medicine. 101(48). e31716–e31716. 2 indexed citations
3.
4.
Zhou, Zili, Shu Yan, Haijun Bao, et al.. (2022). Stress-induced epinephrine promotes epithelial-to-mesenchymal transition and stemness of CRC through the CEBPB/TRIM2/P53 axis. Journal of Translational Medicine. 20(1). 262–262. 40 indexed citations
5.
Zhao, Nancy Q., et al.. (2020). An update on the status of COVID-19: a comprehensive review.. PubMed. 24(8). 4597–4606. 20 indexed citations
6.
Tang, Qiang, Jinhuang Chen, Ziyang Di, et al.. (2020). TM4SF1 promotes EMT and cancer stemness via the Wnt/β-catenin/SOX2 pathway in colorectal cancer. Journal of Experimental & Clinical Cancer Research. 39(1). 232–232. 214 indexed citations
7.
Zhou, Zili, Ning Zhao, Yan Shu, et al.. (2020). Effect of Gastrointestinal Symptoms in Patients With COVID-19. Gastroenterology. 158(8). 2294–2297. 184 indexed citations
8.
Wu, Liang, Wenzheng Yuan, Jinhuang Chen, et al.. (2019). Increased miR-214 expression suppresses cell migration and proliferation in Hirschsprung disease by interacting with PLAGL2. Pediatric Research. 86(4). 460–470. 19 indexed citations
9.
Wu, Liang, Zili Zhou, Shengbo Han, et al.. (2019). PLAGL2 promotes epithelial–mesenchymal transition and mediates colorectal cancer metastasis via β-catenin-dependent regulation of ZEB1. British Journal of Cancer. 122(4). 578–589. 31 indexed citations
10.
Chen, Jinhuang, Wenzheng Yuan, Hailong Ruan, et al.. (2018). Nuclear factor I/B promotes colorectal cancer cell proliferation, epithelial‐mesenchymal transition and 5‐fluorouracil resistance. Cancer Science. 110(1). 86–98. 35 indexed citations
11.
Yuan, Wenzheng, Jintong Ji, Yan Shu, et al.. (2018). Downregulation of DAPK1 promotes the stemness of cancer stem cells and EMT process by activating ZEB1 in colorectal cancer. Journal of Molecular Medicine. 97(1). 89–102. 30 indexed citations
12.
Jiang, Bin, Jinhuang Chen, Wenzheng Yuan, et al.. (2017). Platelet-derived growth factor-D promotes colorectal cancer cell migration, invasion and proliferation by regulating Notch1 and matrix metalloproteinase-9. Oncology Letters. 15(2). 1573–1579. 20 indexed citations
13.
Meng, Qingliang, et al.. (2017). MEK inhibitor enhances sensitivity to chemotherapeutic drugs in multidrug resistant hepatocellular carcinoma cells. Oncology Letters. 14(3). 3089–3095. 4 indexed citations
14.
Yuan, Wenzheng, Jinhuang Chen, Yan Shu, et al.. (2017). Correlation of DAPK1 methylation and the risk of gastrointestinal cancer: A systematic review and meta-analysis. PLoS ONE. 12(9). e0184959–e0184959. 32 indexed citations
15.
Jiang, Bin, Jinhuang Chen, Wenzheng Yuan, et al.. (2016). Prognostic and clinical value of Sirt1 expression in gastric cancer: A systematic meta-analysis. Journal of Huazhong University of Science and Technology [Medical Sciences]. 36(2). 278–284. 10 indexed citations
16.
Chen, Jinhuang, Wenzheng Yuan, Liang Wu, et al.. (2016). PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1/Twist1 pathway. Oncotarget. 8(6). 9961–9973. 66 indexed citations
17.
Chen, Jinhuang, Qinghua Xia, Bin Jiang, et al.. (2015). Prognostic Value of Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. PLoS ONE. 10(12). e0145164–e0145164. 51 indexed citations
18.
Hu, Shanshan, et al.. (2012). Vascular Smooth Muscle Cell Apoptosis Promotes Transplant Arteriosclerosis Through Inducing the Production of SDF-1α. American Journal of Transplantation. 12(8). 2029–2043. 26 indexed citations
19.
Tong, Qiang, Hang Li, Weiyong Li, et al.. (2011). <I>In Vitro</I> and <I>In Vivo</I> Anti-Tumor Effects of Gemcitabine Loaded with a New Drug Delivery System. Journal of Nanoscience and Nanotechnology. 11(4). 3651–3658. 12 indexed citations
20.
Tong, Qiang, Xiaogang Shu, Xiaoming Lu, et al.. (2009). [Effects of magnetic gemcitabine stealth nano-liposomes on the characteristics of breast cancer cell line MCF-7].. PubMed. 44(2). 181–7. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maoming Xiong Breakdown of academic impact, for papers by Shuangfeng Chen Breakdown of academic impact, for papers by Ibrahim Y. Hachim Breakdown of academic impact, for papers by Fangxu Tang Breakdown of academic impact, for papers by Minghua Ge Breakdown of academic impact, for papers by Liyun Cao Breakdown of academic impact, for papers by Yao Xie Breakdown of academic impact, for papers by Jiaqi Zhu Breakdown of academic impact, for papers by Zhilei Lv Breakdown of academic impact, for papers by Lijuan Fang
Rankless by CCL
2026